Related Experiment Videos
A monoclonal antibody raised against Alzheimer cortex that specifically recognizes a subpopulation of microglial
1Laboratory of Neuropathology, Born Bunge Foundation, University of Antwerp, Wilrijk, Belgium.
Abstract:
A monoclonal antibody (MAb), termed AMC30, was raised after in vitro immunization with sonicated neurofibrillary tangle (NFT)-enriched fractions prepared from Alzheimer's brain. The antigen to which AMC30 is directed was expressed by microglial cells in senile plaques of Alzheimer's disease (AD). Microglia in the parenchyma surrounding brain tumors or infarctions, multinuclear giant cells, perivascular and parenchymal macrophages throughout the brain of AIDS patients were also labeled. Different non-nervous system lesions in which macrophages participate were also stained. Microglial cells in normal areas of the cortex or white matter were not labeled with MAb AMC30. The antigen to which AMC30 is directed was not detected in normal bone marrow, lymph nodes, lung, or spleen monocytes or macrophages. The epitope recognized by MAb AMC30 was present after formalin fixation and paraffin embedding. Our findings suggest that this MAb is directed against an antigen that is specifically expressed in a subpopulation of microglial cells and macrophages reactive to various pathological conditions.
Insights
A new antibody, AMC30, targets a specific antigen on reactive microglial cells and macrophages in Alzheimer's disease and other brain pathologies. This antibody shows promise for diagnosing and studying these conditions.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Alzheimer's disease (AD) is characterized by neurofibrillary tangles (NFTs).
- Microglial cells and macrophages play crucial roles in brain pathology.
- Identifying specific markers for reactive glial cells is important for understanding disease mechanisms.
Purpose of the Study:
- To develop and characterize a novel monoclonal antibody (MAb), AMC30.
- To identify the specific antigen recognized by AMC30.
- To evaluate the expression pattern of the AMC30 antigen in various pathological conditions.
Main Methods:
- In vitro immunization using sonicated NFT-enriched fractions from Alzheimer's brain.
- Immunohistochemical staining of brain tissue from Alzheimer's disease patients, individuals with brain tumors or infarctions, and AIDS patients.
- Staining of non-nervous system lesions and normal tissues (bone marrow, lymph nodes, lung, spleen).
- Assessment of antigen stability after formalin fixation and paraffin embedding.
Main Results:
- MAb AMC30 specifically labeled microglial cells in senile plaques of Alzheimer's disease brains.
- The antigen was also expressed by microglia surrounding brain tumors/infarctions, multinuclear giant cells, and macrophages in AIDS brains.
- Macrophages in various non-nervous system lesions were stained.
- No labeling was observed in normal microglial cells or monocytes/macrophages from normal organs.
- The epitope recognized by AMC30 is stable after formalin fixation and paraffin embedding.
Conclusions:
- MAb AMC30 recognizes an antigen specifically expressed on a subpopulation of reactive microglial cells and macrophages.
- This antigen is associated with pathological conditions including Alzheimer's disease, brain tumors, infarctions, and AIDS.
- AMC30 is a valuable tool for studying reactive glial cells and macrophages in neuropathology and potentially for diagnostic applications.